What Filigra Treats: Main Uses and Benefits

Filigra (sildenafil) is a prescription medication utilized in therapeutic domains for specific conditions. Its primary approved use is to address the symptoms of erectile dysfunction (ED) in adult men, which involves the ability to achieve or sustain an erection sufficient for satisfactory sexual activity. The medication supports the restoration of erectile function when sexual stimulation is present.

---

Filigra is also indicated to manage pulmonary arterial hypertension (PAH), a type of high blood pressure that impacts the arteries in the lungs and the right side of the heart. For individuals with PAH, the medication contributes to improved exercise capacity and may assist in delaying clinical worsening related to the condition.

---

Quick Facts on Filigra

• Therapeutic Domain 1: Management of erectile dysfunction (ED).
• Therapeutic Domain 2: Improvement of exercise ability in individuals with pulmonary arterial hypertension (PAH).
• Primary Action: Supports erectile function in adult males when sexual stimulation is present.

Who Can and Cannot Use Filigra?

The eligibility to use Filigra (sildenafil) is strictly determined by regulatory rules, based on the patient's condition and the specific therapeutic indication—Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH).

Absolute Contraindications (Cannot Use)

Filigra is strictly contraindicated and must not be used by patients who:

• Are taking any form of organic nitrates or nitric oxide donors (due to severe risk of hypotension).
• Are taking a soluble guanylate cyclase (sGC) stimulator, such as riociguat.
• Have experienced loss of vision in one eye due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).
• Have certain severe pre-existing cardiovascular conditions, such as recent stroke or myocardial infarction (within 6 months), or severe hepatic impairment (Child-Pugh Class C).

---

Conditional and Restricted Use

Population	Eligibility Note
Age Groups	Approved for adult men (ED) and adults/pediatrics (age 1+) for PAH. Use is not established in infants under one year old.
Organ Impairment	Patients with severe renal impairment or hepatic impairment require a lower starting dose (for ED indication).
Women	Filigra for the ED indication is not indicated for use by women.

These constraints define the official boundaries for safe and appropriate use, as documented in regulatory prescribing information.

Interactions with other medicines and products

The interaction profile of Filigra is defined by the risks of additive pharmacological effects and altered metabolic clearance. All interaction information below is based on official government regulatory documents.

Contraindicated Combinations

Co-administration with the following substances is strictly contraindicated due to the risk of severe, potentially fatal, pharmacodynamic potentiation of hypotensive effects:

• Any form of Organic Nitrates or Nitric Oxide Donors (e.g., Nitroglycerin, Amyl Nitrite).
• Guanylate Cyclase (GC) Stimulators, such as Riociguat.

Drug-Drug Interaction Effects

Interaction patterns involve both metabolic and additive cardiovascular effects:

• Pharmacokinetic Inhibition: Strong CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) cause a substantial increase in Sildenafil plasma exposure by reducing metabolic clearance. This increased exposure is managed by specific regulatory limitations on administration frequency.
• Pharmacodynamic Potentiation: Co-administration with Alpha-blockers or other Anti-hypertensive Medications may lead to symptomatic hypotension due to additive blood pressure-lowering effects.
• Other PDE5 Inhibitors are not recommended for co-administration.

Food and Population Interactions

• A high-fat meal results in an interaction that reduces the rate of absorption and the maximum plasma concentration ( C max) of Sildenafil.
• Official documentation notes that increased plasma levels are associated with advanced age (65 years and older) and patients with hepatic or severe renal impairment.

Filigra is classified as a selective cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor.

Molecular and Intracellular Pathway

Filigra competitively binds to the active site of the PDE5 enzyme, an interaction that prevents the hydrolysis and degradation of the intracellular messenger cGMP in smooth muscle cells.

Under conditions of upstream stimulation (e.g., nitric oxide release), the resulting accumulation of cGMP in the cytoplasm enhances the activity of cGMP-dependent protein kinase (PKG). The subsequent phosphorylation of various intracellular target proteins, including ion channels and calcium regulatory proteins, drives a reduction in intracellular calcium concentration. This reduction leads to the dephosphorylation of myosin light chain kinase, ultimately resulting in vascular smooth muscle relaxation.

System-level Physiological Consequences

This cellular relaxation mechanism causes vasodilation in tissues where PDE5 is expressed, notably the smooth muscle of the pulmonary vasculature and the corpus cavernosum within the penile tissue. The resulting systemic physiological modulation is a decrease in vascular resistance and an increase in regional blood flow to the targeted areas.

Filigra (sildenafil) administration guidelines vary significantly depending on the therapeutic indication. The medicine is used for both oral ingestion (tablet and suspension forms) and intravenous (IV) injection; the IV route is reserved for the management of PAH in patients temporarily unable to take oral forms.

Dosing and Frequency by Indication

For addressing erectile dysfunction (ED), Filigra is used on an as-needed basis, with a maximum frequency of once per day. The usual starting oral dose is 50 mg, which may be adjusted within a range of 25 mg to 100 mg per dose. Administration should occur approximately one hour before activity, noting that consumption with a high-fat meal may reduce the rate of absorption.

In the management of pulmonary arterial hypertension (PAH), the usage pattern is continuous, requiring the medicine to be taken on a three-times-a-day (TID) schedule, with doses separated by four to six hours. The standard oral dose is 20 mg. The IV formulation is administered as a 10 mg bolus.

Population-Specific Adjustments

Dose modulation is utilized for certain populations. For the ED indication, an initial oral dose of 25 mg is considered for older adults (65 years and above) or in the presence of severe renal or hepatic impairment. This approach ensures the administration protocol remains appropriate for these specific patient groups.

Filigra (sildenafil) is a phosphodiesterase type 5 (PDE5) inhibitor researched primarily for its use in treating two distinct conditions: erectile dysfunction (ED) and pulmonary arterial hypertension (PAH).

Clinical Efficacy in Erectile Dysfunction

• Improvement in Function: Multiple randomized, placebo-controlled clinical trials consistently indicate that Filigra use is associated with improvements in erectile function, specifically in the ability to attain and maintain an erection adequate for sexual intercourse. Pooled data from trials suggest a significantly higher rate of successful sexual attempts in men using the medication compared to those on placebo.
• Patient Subgroups: Studies have demonstrated efficacy across broad patient populations, including men with ED related to conditions such as diabetes mellitus and following radical prostatectomy, although response rates may vary by subgroup.
• Duration of Effect: Long-term studies, some extending up to one year, indicate that the reported improvements in erectile function are generally sustained over time, with low rates of discontinuation due to insufficient response.

Clinical Efficacy in Pulmonary Arterial Hypertension

• Exercise Capacity: Research, including controlled trials, supports the use of Filigra in adult patients with WHO functional class II and III PAH. Treatment with the drug has been consistently associated with improved exercise capacity, typically measured by the six-minute walk distance test.
• Pediatric Use: Evidence also supports the use of Filigra in some pediatric patients (ages 1 to 17) with PAH. Efficacy in this population is generally assessed by improvements in exercise capacity or pulmonary hemodynamics. Filigra is sometimes used in PAH associated with congenital heart disease.

General Safety Profile in Research

Clinical trials report that the most frequently observed adverse events are generally transient and mild to moderate in severity. These commonly include headache, flushing, and dyspepsia (indigestion). Post-marketing surveillance data, which gathers broader real-world information, has been monitored for rare, more serious cardiovascular and visual events, particularly in patients with pre-existing risk factors.

Common questions about Filigra (FAQ)

---

Q: How quickly does Filigra typically start to work after taking it?

According to official product information, the maximum concentration of Filigra in the bloodstream is typically reached about one hour after the oral dose is taken. This time may be delayed if the medication is consumed with a high-fat meal.

---

Q: How long does the effect of Filigra last?

Studies and official information indicate that the pharmacological activity for the medication's primary effects is generally described as lasting for approximately four hours after administration. This duration is related to the compound's half-life, though trace amounts may remain in the body for longer periods.

---

Q: Can Filigra be taken if I am already taking medication for blood pressure?

Regulatory documents note that taking Filigra alongside other anti-hypertensive medications, such as alpha-blockers, may result in additive blood pressure-lowering effects. This combination carries a potential risk of symptomatic hypotension (abnormally low blood pressure).

---

Q: What is the difference between Filigra and other similar medicines?

Filigra belongs to a class of medicines known as PDE5 inhibitors. Official information describes other medicines in this class as having differing properties, such as a potentially longer duration of action or a variation in the time required for the onset of effect compared to Filigra.

---

Q: Is there a maximum amount of time someone can take Filigra?

For the primary adult indication, clinical trials indicate that improvements were sustained over periods up to one year. However, for the pediatric pulmonary arterial hypertension (PAH) indication, chronic use of higher doses is not recommended by regulatory bodies due to specific safety findings noted in clinical trials.

---

Q: What happens if I miss a dose of Filigra?

Regulatory guidance describes that for a continuous treatment regimen (such as for PAH), if a dose is missed, patients are generally advised to take it as soon as it is remembered, unless it is near the time of the next scheduled dose. If so, skipping the missed dose is the described protocol to ensure the maximum dosing frequency is not exceeded.

---

Q: Does Filigra cause drowsiness or affect driving?

Official labeling states that side effects like dizziness and visual disturbances have been reported with the use of Filigra. Due to these potential effects, the official labeling includes a precaution regarding driving or operating machinery until the individual knows how the medication may affect them.

---

Q: Does Filigra interact with alcohol?

Regulatory documents indicate that the co-consumption of alcohol is associated with a greater risk of low blood pressure effects from Filigra. This information suggests a need for caution regarding the use of alcohol while taking this medication.

---

Q: Can I take Filigra if I am pregnant or breastfeeding?

The medication is not indicated for women for the erectile dysfunction use. For the pulmonary arterial hypertension (PAH) indication, studies show sildenafil and its active metabolite are poorly excreted into breast milk. Use during pregnancy or breastfeeding is based on the serious nature of the mother's underlying condition and is determined by a healthcare provider.

---

Q: Can Filigra affect the results of lab tests?

Official prescribing information indicates that Filigra is not known to affect the results of standard laboratory tests.

Storage and Disposal Requirements for Filigra (Sildenafil Tablets)

The official labeling for Filigra tablets requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be kept in its original, tight container and protected from moisture to maintain product stability. Do not use the tablets past the expiration date on the package.

Child Safety and Disposal

All medication must be stored out of the sight and reach of children. Unused or expired Filigra should not be disposed of by flushing down the toilet. The preferred method for discarding the medicine is through a drug take-back program. If one is unavailable, dispose of the tablets in the household trash after mixing them with an unpalatable substance like coffee grounds and sealing them in a bag.